Transition From Biomarkers To Surrogate Endpoints Will Be Subcmte. Topic
This article was originally published in The Pink Sheet Daily
Executive Summary
The subcommittee will focus on the planning and process of the transition from biomarkers to surrogate endpoints for drugs under FDA’s “Critical Path” initiative. Updating approved drug labeling to include pharmacogenetic information will also be discussed at the Nov. 3-4 meeting.